Last updated: February 22, 2026
What Is the Drug NDC 51660-0143?
NDC 51660-0143 corresponds to Odomzo (sonidegib), marketed by Sun Pharmaceutical Industries. It is an oral hedgehog pathway inhibitor approved by the FDA in 2015 for treating locally advanced basal cell carcinoma (BCC) that cannot be surgically removed or radiated.
Market Size and Demand Drivers
The primary market comprises patients with locally advanced or metastatic basal cell carcinoma (BCC), a condition with approximately 4 million cases annually in the U.S.
Key Factors:
- Approved Indications: Hedgehog pathway inhibitors, including sonidegib, are second-line treatments after hedgehog pathway mutation detection.
- Market Penetration: Sonidegib faces competition from similar drugs such as vismodegib (Erivedge), offering similar efficacy.
- Patient Population: Estimated 10% of BCC patients develop advanced forms requiring systemic therapy.
- Treatment Duration: Typically 6–12 months per course, influencing sales volume growth.
Market Size Estimates:
| Metric |
Value |
Source |
| U.S. BCC incidence (annual) |
~4 million cases |
American Cancer Society[1] |
| Advanced BCC patients (estimated) |
10-20% of total BCC cases |
Peer-reviewed estimates[2] |
| Patients eligible for systemic therapy |
~400,000 – 800,000 annually |
Derived from incidence and progression rates |
| Estimated market size (US) |
Potentially 30,000 – 60,000 patients |
Conservative estimate based on market penetration with current competition[3] |
Competitive Landscape
- Vismodegib (Erivedge): Approved in 2012; dominates the market.
- Sonidegib (Odomzo): Approved in 2015; shares indications but has limited market share.
- Emerging Therapies: Research on combination therapies and newer hedgehog inhibitors progressing.
Pricing and Revenue Trends
Current Pricing:
- Average wholesale price (AWP): Approximately $6,000 – $7,000 per month for a 200 mg capsule.
- Average retail price: The monthly cost translates roughly to $70,000 – $84,000 per treatment course, depending on dose and duration.
Revenue Assumptions:
| Variable |
Value |
Sources |
| Monthly price per patient |
$6,500 – $7,000 |
AWP, drug pricing databases[4] |
| Average treatment duration |
6–12 months |
Clinical guidelines[5] |
| Estimated patient base (US) |
30,000 – 60,000 |
Based on market size estimates |
| Market share assumption |
10–15% |
Current drug market dynamics |
Projected US revenue potential:
| Scenario |
Annual Revenue (USD) |
| Conservative (10% market share, 6-month treatment) |
~$100 million [$6,500 x 6 months x 30,000 patients] |
| Optimistic (15% market share, 12-month treatment) |
~$180 million [$7,000 x 12 months x 60,000 patients] |
Price Projections (Next 5 Years):
- Price could decrease by 10-15% due to biosimilar and generic competition anticipated post-2025.
- Market growth projections for advanced BCC treatments are modest, at approximately 2-3% annually, buffered by regulatory developments and enhanced clinical adoption.
Regulatory and Pricing Policies Impact
- The US Medicare/Medicaid Drug Rebate Program influences discounts and net pricing.
- Price increases are limited by payer negotiations and value-based pricing reforms.
Future Trends Affecting Price and Market Size
- Orphan Drug Designation: Offers 7-year market exclusivity, promoting pricing power.
- Biosimilar Competition: Entry expected after patent expiry (~2030).
- Precision Medicine: Better biomarkers might expand eligible patient populations.
- Global Expansion: Markets like Europe and Asia-Pacific present additional revenue pathways, with lower price points.
Key Takeaways
- The U.S. market for NDC 51660-0143 (sonidegib) will remain consolidating, with an estimated 10–15% market share of the advanced BCC population.
- Current pricing ranges around $6,500–$7,000 per month, translated into potential revenues of approximately $100–$180 million annually in the U.S.
- Price erosion of 10–15% is probable through biosimilar entry over the next 3–5 years.
- Market growth is supported by the prevalence of advanced BCC, but constrained by competition and payer strategies.
- Future expansions depend on clinical success, regulatory approvals, and market penetration strategies.
FAQs
Q1: When is the patent expiry for sonidegib?
A1: The primary patent is expected to expire around 2030, with some patents potentially extending to 2035 after filings and extensions.
Q2: Who are the main competitors to NDC 51660-0143?
A2: Vismodegib (Erivedge) is the main competitor, with other investigational hedgehog pathway inhibitors in development.
Q3: What is the likelihood of price reductions in the next five years?
A3: High; patent protections and market dynamics forecast a 10–15% price decrease post-biosimilar entry around 2025–2030.
Q4: How many patients are currently likely to be treated annually in the US?
A4: Between 30,000 and 60,000 patients, depending on market share and treatment duration.
Q5: What opportunities exist for expanding market share?
A5: Investing in clinical evidence for broader indications, geographic expansion, and payer negotiations can improve sales.
References
- American Cancer Society. (2022). Basal Cell Carcinoma Statistics. Retrieved from https://cancerstatisticscenter.cancer.org
- Chang, A. L., et al. (2020). Epidemiology and clinical features of advanced basal cell carcinoma. Journal of Clinical Oncology, 38(17), 1906–1914.
- IQVIA. (2022). US Oncology Market Insights.
- RED BOOK. (2023). Drug Pricing and Wholesale Invoice Data.
- National Comprehensive Cancer Network (NCCN). (2023). Basal Cell Skin Cancer Guidelines.
